Insulet Net Worth
Insulet Net Worth Breakdown | PODD |
Insulet Net Worth Analysis
Insulet's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Insulet's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Insulet's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Insulet's net worth analysis. One common approach is to calculate Insulet's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Insulet's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Insulet's net worth. This approach calculates the present value of Insulet's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Insulet's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Insulet's net worth. This involves comparing Insulet's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Insulet's net worth relative to its peers.
Enterprise Value |
|
To determine if Insulet is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Insulet's net worth research are outlined below:
| Insulet is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insulet Corp Stock Price Down 7. percent on Feb 25 |
Insulet Quarterly Good Will |
|
Insulet uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Insulet. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Insulet's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Insulet Target Price Consensus
Insulet target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Insulet's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 23 | Strong Buy |
Most Insulet analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Insulet stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Insulet, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationInsulet Target Price Projection
Insulet's current and average target prices are 270.64 and 292.08, respectively. The current price of Insulet is the price at which Insulet is currently trading. On the other hand, Insulet's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Insulet Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Insulet Target Price
Know Insulet's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insulet is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insulet backward and forwards among themselves. Insulet's institutional investor refers to the entity that pools money to purchase Insulet's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-12-31 | 1.2 M | Jpmorgan Chase & Co | 2024-09-30 | 1.1 M | Groupama Asset Management | 2024-12-31 | 1.1 M | Citadel Advisors Llc | 2024-09-30 | 990.5 K | Norges Bank | 2024-12-31 | 953 K | American Century Companies Inc | 2024-12-31 | 854.9 K | Artisan Partners Limited Partnership | 2024-12-31 | 770.2 K | Northern Trust Corp | 2024-12-31 | 738.8 K | Macquarie Group Ltd | 2024-12-31 | 691 K | Vanguard Group Inc | 2024-12-31 | 8.5 M | Fmr Inc | 2024-12-31 | 7.8 M |
Follow Insulet's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 18.73 B.Market Cap |
|
Project Insulet's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.12 | 0.13 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.35 | 0.36 |
When accessing Insulet's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Insulet's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Insulet's profitability and make more informed investment decisions.
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.
Evaluate Insulet's management efficiency
Insulet has return on total asset (ROA) of 0.068 % which means that it generated a profit of $0.068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4303 %, meaning that it created $0.4303 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.15. The current year's Return On Capital Employed is expected to grow to 0.13. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.3 B, whereas Intangibles To Total Assets are forecasted to decline to 0.05.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 17.29 | 18.15 | |
| Tangible Book Value Per Share | 15.15 | 15.91 | |
| Enterprise Value Over EBITDA | 56.41 | 96.63 | |
| Price Book Value Ratio | 15.10 | 19.90 | |
| Enterprise Value Multiple | 56.41 | 96.63 | |
| Price Fair Value | 15.10 | 19.90 | |
| Enterprise Value | 9.8 B | 10.3 B |
Management at Insulet focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 9.8226 | Revenue | Quarterly Revenue Growth 0.172 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insulet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insulet Corporate Filings
10K | 21st of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 20th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Insulet Earnings Estimation Breakdown
The calculation of Insulet's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Insulet is estimated to be 0.7657 with the future projection ranging from a low of 0.63 to a high of 1.16. Please be aware that this consensus of annual earnings estimates for Insulet is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.63 Lowest | Expected EPS | 1.16 Highest |
Insulet Earnings Projection Consensus
Suppose the current estimates of Insulet's value are higher than the current market price of the Insulet stock. In this case, investors may conclude that Insulet is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Insulet's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 23 | 57.36% | 1.15 | 0.7657 | 5.78 |
Insulet Earnings per Share Projection vs Actual
Actual Earning per Share of Insulet refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Insulet predict the company's earnings will be in the future. The higher the earnings per share of Insulet, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Insulet Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Insulet, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Insulet should always be considered in relation to other companies to make a more educated investment decision.Insulet Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Insulet's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-20 | 2024-12-31 | 1.021 | 1.15 | 0.129 | 12 | ||
2024-11-07 | 2024-09-30 | 0.76 | 0.9 | 0.14 | 18 | ||
2024-08-08 | 2024-06-30 | 0.56 | 0.55 | -0.01 | 1 | ||
2024-05-09 | 2024-03-31 | 0.39 | 0.73 | 0.34 | 87 | ||
2024-02-22 | 2023-12-31 | 0.66 | 1.4 | 0.74 | 112 | ||
2023-11-02 | 2023-09-30 | 0.4 | 0.71 | 0.31 | 77 | ||
2023-08-08 | 2023-06-30 | 0.26 | 0.38 | 0.12 | 46 | ||
2023-05-04 | 2023-03-31 | 0.11 | 0.23 | 0.12 | 109 | ||
2023-02-23 | 2022-12-31 | 0.21 | 0.24 | 0.03 | 14 | ||
2022-11-03 | 2022-09-30 | 0.15 | 0.35 | 0.2 | 133 | ||
2022-08-04 | 2022-06-30 | 0.22 | -0.5 | -0.72 | 327 | ||
2022-05-05 | 2022-03-31 | 0.23 | 0.4 | 0.17 | 73 | ||
2022-02-23 | 2021-12-31 | 0.32 | 0.42 | 0.1 | 31 | ||
2021-11-04 | 2021-09-30 | 0.24 | 0.18 | -0.06 | 25 | ||
2021-08-05 | 2021-06-30 | 0.13 | 0.23 | 0.1 | 76 | ||
null | null | null | null | null | 0 | ||
2021-02-23 | 2020-12-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2020-11-04 | 2020-09-30 | 0.08 | 0.17 | 0.09 | 112 | ||
2020-08-06 | 2020-06-30 | 0.011 | 0.22 | 0.209 | 1900 | ||
2020-05-07 | 2020-03-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2020-02-25 | 2019-12-31 | 0.11 | 0.08 | -0.03 | 27 | ||
2019-11-05 | 2019-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2019-08-05 | 2019-06-30 | 0.02 | 0.02 | 0.0 | 0 | ||
2019-05-02 | 2019-03-31 | 0.01 | 0.07 | 0.06 | 600 | ||
2019-02-25 | 2018-12-31 | 0.07 | 0.16 | 0.09 | 128 | ||
2018-11-01 | 2018-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2018-08-02 | 2018-06-30 | -0.13 | -0.03 | 0.1 | 76 | ||
2018-05-03 | 2018-03-31 | -0.19 | -0.11 | 0.08 | 42 | ||
2018-02-21 | 2017-12-31 | -0.08 | -0.12 | -0.04 | 50 | ||
2017-11-02 | 2017-09-30 | -0.1 | -0.04 | 0.06 | 60 | ||
2017-08-03 | 2017-06-30 | -0.13 | -0.13 | 0.0 | 0 | ||
2017-05-08 | 2017-03-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2017-02-27 | 2016-12-31 | -0.05 | -0.16 | -0.11 | 220 | ||
2016-11-03 | 2016-09-30 | -0.09 | -0.05 | 0.04 | 44 | ||
2016-08-03 | 2016-06-30 | -0.17 | -0.08 | 0.09 | 52 | ||
2016-04-28 | 2016-03-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2016-02-25 | 2015-12-31 | -0.26 | -0.28 | -0.02 | 7 | ||
2015-11-05 | 2015-09-30 | -0.26 | -0.33 | -0.07 | 26 | ||
2015-08-12 | 2015-06-30 | -0.13 | -0.27 | -0.14 | 107 | ||
2015-04-30 | 2015-03-31 | -0.1 | -0.21 | -0.11 | 110 | ||
2015-02-26 | 2014-12-31 | -0.04 | -0.1 | -0.06 | 150 | ||
2014-11-05 | 2014-09-30 | -0.01 | -0.12 | -0.11 | 1100 | ||
2014-08-07 | 2014-06-30 | -0.08 | -0.06 | 0.02 | 25 | ||
2014-05-07 | 2014-03-31 | -0.06 | -0.11 | -0.05 | 83 | ||
2014-02-27 | 2013-12-31 | -0.09 | -0.04 | 0.05 | 55 | ||
2013-11-07 | 2013-09-30 | -0.16 | -0.21 | -0.05 | 31 | ||
2013-08-07 | 2013-06-30 | -0.19 | -0.2 | -0.01 | 5 | ||
2013-05-06 | 2013-03-31 | -0.21 | -0.2 | 0.01 | 4 | ||
2013-02-27 | 2012-12-31 | -0.22 | -0.21 | 0.01 | 4 | ||
2012-11-08 | 2012-09-30 | -0.24 | -0.26 | -0.02 | 8 | ||
2012-08-08 | 2012-06-30 | -0.26 | -0.3 | -0.04 | 15 | ||
2012-05-09 | 2012-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2012-02-09 | 2011-12-31 | -0.26 | -0.3 | -0.04 | 15 | ||
2011-11-03 | 2011-09-30 | -0.25 | -0.29 | -0.04 | 16 | ||
2011-08-02 | 2011-06-30 | -0.23 | -0.42 | -0.19 | 82 | ||
2011-05-09 | 2011-03-31 | -0.22 | -0.22 | 0.0 | 0 | ||
2011-02-15 | 2010-12-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2010-11-09 | 2010-09-30 | -0.3 | -0.3 | 0.0 | 0 | ||
2010-07-29 | 2010-06-30 | -0.35 | -0.36 | -0.01 | 2 | ||
2010-05-06 | 2010-03-31 | -0.38 | -0.37 | 0.01 | 2 | ||
2010-02-09 | 2009-12-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2009-10-26 | 2009-09-30 | -0.7 | -0.88 | -0.18 | 25 | ||
2009-08-04 | 2009-06-30 | -0.68 | -0.73 | -0.05 | 7 | ||
2009-05-07 | 2009-03-31 | -0.65 | -0.71 | -0.06 | 9 | ||
2009-03-05 | 2008-12-31 | -0.63 | -1.02 | -0.39 | 61 | ||
2008-11-06 | 2008-09-30 | -0.74 | -0.75 | -0.01 | 1 | ||
2008-08-12 | 2008-06-30 | -0.7 | -0.87 | -0.17 | 24 | ||
2008-05-13 | 2008-03-31 | -0.56 | -0.73 | -0.17 | 30 | ||
2008-03-17 | 2007-12-31 | -0.51 | -0.59 | -0.08 | 15 | ||
2007-11-14 | 2007-09-30 | -0.5 | -0.52 | -0.02 | 4 | ||
2007-08-14 | 2007-06-30 | -0.56 | -0.99 | -0.43 | 76 |
Insulet Corporate Management
| Philip Hildale | Senior Care | Profile | |
| Andrew Isaacson | Senior Development | Profile | |
| Prem Singh | Senior Operations | Profile | |
| Laetitia Cousin | Quality Affairs | Profile | |
| John JD | Senior Counsel | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 5.78 | Revenue Per Share | Quarterly Revenue Growth 0.172 | Return On Assets |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.